KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $0.66.

  • Pfizer's Debt to Equity fell 937.3% to $0.66 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.66, marking a year-over-year decrease of 937.3%. This contributed to the annual value of $0.73 for FY2024, which is 1026.1% down from last year.
  • Pfizer's Debt to Equity amounted to $0.66 in Q3 2025, which was down 937.3% from $0.69 recorded in Q2 2025.
  • In the past 5 years, Pfizer's Debt to Equity registered a high of $1.96 during Q4 2022, and its lowest value of $0.35 during Q2 2023.
  • Over the past 5 years, Pfizer's median Debt to Equity value was $0.66 (recorded in 2025), while the average stood at $0.71.
  • The largest annual percentage gain for Pfizer's Debt to Equity in the last 5 years was 11622.11% (2023), contrasted with its biggest fall of 6666.73% (2023).
  • Over the past 5 years, Pfizer's Debt to Equity (Quarter) stood at $0.5 in 2021, then fell by 24.47% to $0.37 in 2022, then skyrocketed by 116.22% to $0.81 in 2023, then fell by 10.26% to $0.73 in 2024, then dropped by 8.84% to $0.66 in 2025.
  • Its last three reported values are $0.66 in Q3 2025, $0.69 for Q2 2025, and $0.69 during Q1 2025.